BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, a privately owned biopharmaceutical company.
Aucta Pharmaceuticals, Inc. (Aucta) has partnered with Oakrum Pharma, out of St. Louis, Missouri, to announce the U.S. launch of a generic version of JADENU® Sprinkle (Deferasirox Granules) in 90mg, 180mg, and 360mg strengths.
The Toxo Total Care program was created by Oakrum to provide patients with toxoplasmosis and their healthcare providers the quality and service of a branded specialty drug for its authorized generic pyrimethamine 25 mg tablets. Some of the anticipated benefits of the Toxo Total Care program include:
PR NEWSWIRE
Oakrum Pharma & Biophore Announce Product Development Partnership
Oakrum Pharma and Biophore Announce Product Development and Commercialization Partnership
Oakrum Pharma, LLC (Oakrum) announced today that it has entered into an agreement with Biophore India Pharmaceuticals Pvt. Ltd. (Biophore) to develop and manufacture two prescription generic pharmaceutical products that are intended to be commercialized in the U.S. under the Oakrum label. It is anticipated that both products will be sold through the specialty distribution market channel. The total market for the products in the U.S. exceeded $150 million in aggregate sales for the 12-month period ending December 31, 2018 according to Bloomberg® data.